Supernus Pharmaceuticals (SUPN) concentration risks

The company's disclosed concentration profile combines a high-share distributor dependency and two product-level exposures of differing scale. On the customer side, three specialty pharmaceutical distributors — Cencora, Cardinal Health, and McKesson — collectively accounted for more than 76% of total product revenue in 2025, a high-share dependency. This channel concentration is characteristic of the U.S. specialty pharmaceutical market, where the "Big Three" wholesalers control the dominant share of distribution. The dependency character means that changes in purchasing terms, inventory management practices, or contract arrangements with any of these distributors could affect revenue timing and visibility. On the product side, Qelbree represented approximately 49% of total net revenues for the year ended December 31, 2025, a moderate-share, mixed-character exposure. As the company's largest product by revenue share, Qelbree's prescription volume, reimbursement dynamics, and competitive position are the single most important product-level driver of results. GOCOVRI contributed approximately 23% of total net revenues for the same period, a lower-share, mixed-character exposure that provides some product diversification but at a scale where a market share shift or generic entry would have a more limited aggregate impact than a similar event affecting Qelbree. The three exposures interact: the distributor concentration is the channel through which both Qelbree and GOCOVRI reach the market, meaning the company's revenue from its top two products flows almost entirely through three wholesale relationships. Any disruption — at the distributor, the product, or both — compounds given the lack of channel diversification.

For the engine’s reasoning on SUPN’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.